bemesetron and dolasetron

bemesetron has been researched along with dolasetron* in 3 studies

Other Studies

3 other study(ies) available for bemesetron and dolasetron

ArticleYear
Attenuation of defensive analgesia in male mice by 5-HT3 receptor antagonists, ICS 205-930, MDL 72222, MDL 73147EF and MDL 72699.
    Neuropharmacology, 1992, Volume: 31, Issue:6

    Recent studies have shown that non-opioid defensive analgesia in male mice is potently inhibited by the 5-HT3 receptor antagonist, ondansetron. The present series of experiments was conducted to further explore the involvement of 5-HT3 receptor mechanisms in this particular form of adaptive inhibition of pain. The drug ICS 205-930 significantly attenuated the reaction at 1.25-2.5 micrograms/kg, with smaller and larger doses being ineffective. Both MDL 72222 and MDL 73147EF produced flat dose-response curves, with significant inhibition of defensive analgesia at minimum effective doses of less than or equal to 10 and 300 micrograms/kg, respectively. Although MDL 72699, the quaternary salt of MDL 72222, also inhibited the reaction, this effect was seen at comparatively large doses (0.5-1.0 mg/kg) only. None of the compounds tested had significant intrinsic effects of tail-flick latencies, over the dose ranges tested. These findings indicate that 5-HT3 receptor mechanisms may have an important modulatory role in certain forms of "stress" analgesia. Data are discussed in relation to the consistent profile of partial inhibition produced by 5-HT3 receptor antagonists in this model.

    Topics: Analgesia; Analysis of Variance; Animals; Dose-Response Relationship, Drug; Hot Temperature; Indoles; Male; Mice; Mice, Inbred DBA; Pain; Posture; Quinolizines; Receptors, Serotonin; Reference Values; Serotonin Antagonists; Stereotyped Behavior; Tropanes; Tropisetron

1992
The effect of 5-HT3 receptor antagonists on the discriminative stimulus effects of amphetamine.
    European journal of pharmacology, 1992, Mar-03, Volume: 212, Issue:2-3

    The discriminative stimulus induced in rats by amphetamine has previously been shown to be due to raised mesolimbic dopamine levels. As 5-HT3 receptor antagonists have been shown to inhibit hyperactivity resulting from raised mesolimbic dopamine levels, the present study examined their effects against the amphetamine discriminative stimulus. None of the 5-HT3 receptor antagonists tested (MDL 72,222EF, 0.3-10 mg/kg s.c.; MDL 73,147EF, 0.3-10 mg/kg s.c.; ICS 205-930, 0.01-10.0 mg/kg s.c.; ondansetron, 0.1-1000 micrograms/kg s.c.) antagonised the effects of amphetamine in this test. This suggests that 5-HT3 receptors cannot modulate the effects of raised mesolimbic dopamine in pathways involved in the interoceptive effects of amphetamine.

    Topics: Amphetamine; Animals; Discrimination Learning; Imidazoles; Indoles; Male; Ondansetron; Quinolizines; Rats; Rats, Inbred Strains; Serotonin Antagonists; Tropanes; Tropisetron

1992
Serotonin antagonists: a new class of antiemetic agents.
    Journal of the National Cancer Institute, 1991, May-01, Volume: 83, Issue:9

    Despite a number of significant advances over the past decade, prevention and treatment of chemotherapy-induced emesis remain formidable problems, particularly with cisplatin-containing regimens. Nearly one third of patients receiving high-dose cisplatin still experience substantial emesis despite the best available conventional antiemetics, and the toxic effects of these agents remain quite troublesome. In recent years, a new class of agents, the serotonin antagonists, has been identified. These agents hold promise for clinical utility in a wide range of areas. Selective antagonists of the serotonin (5-hydroxytryptamine) type 3 (5-HT3) receptor have proven in early clinical trials to be potent antiemetic agents in patients receiving cytotoxic chemotherapy, with efficacy comparable to or superior to that of conventional antiemetics. Toxic effects to date with the 5-HT3 receptor antagonists have been modest. The current state of knowledge with respect to these agents as antiemetics for patients receiving cytotoxic chemotherapy is summarized.

    Topics: Antiemetics; Benzamides; Bridged Bicyclo Compounds; Bridged Bicyclo Compounds, Heterocyclic; Granisetron; Humans; Imidazoles; Indazoles; Indoles; Metoclopramide; Ondansetron; Quinolizines; Receptors, Serotonin; Serotonin Antagonists; Tropanes; Tropisetron; Vomiting

1991